Royal Bank of Canada
CTOR

Royal Bank of Canada’s Citius Oncology CTOR Stock Holding History

Royal Bank of Canada’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
186
+163
+709% +$164 ﹤0.01% 7820
2025
Q4 		$0 Buy
+23
New +$33 ﹤0.01% 7762

Other funds holding CTOR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada's CTOR Position: Q1 2026 in Review

Royal Bank of Canada increased its Citius Oncology (CTOR) stake by 709% in Q1 2026, buying an estimated $164 and bringing the position to 186 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7820.

Royal Bank of Canada first reported a position in CTOR in Q4 2025 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold CTOR as of Q1 2026.

  • Royal Bank of Canada held 186 shares of Citius Oncology worth $0 as of Q1 2026.
  • Royal Bank of Canada bought 163 Citius Oncology shares in Q1 2026, an estimated $164.
  • Citius Oncology made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7820 holding.
  • Royal Bank of Canada first reported a position in Citius Oncology in Q4 2025 and has held it in 2 quarters since.
  • 14 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.